PIK3CA突变与乳腺癌临床病理特征及预后的相关性OACSTPCD
Correlation between PIK3CA mutation and clinicopathological features and prognosis of breast cancer
目的 探讨乳腺癌标本中磷脂酰肌醇激酶-3-催化亚基α(PIK3CA)突变与侵袭性乳腺癌临床病理特征及预后的相关性.方法 收集 2018 年 1 月至 2020 年 1 月确诊为乳腺癌的 181 例患者临床病理资料,用免疫组织化学(IHC)法检测乳腺癌雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体 2(HER2)、Ki-67 等指标,RT-qPCR检测乳腺癌中PIK3CA外显子 9(exon9)和外显子 20(exon20)的突变.结果 181 例侵袭性乳腺癌中PIK3CA突变70 例,其中 31 例(44.28%)exon9 突变、39 例(55.71%)exon20 突变.PIK3CA突变与乳腺癌分子分型有明显差异(P<0.05).PIK3CA突变与乳腺癌的Ki67 表达有明显差异(P<0.05).34 例(48.57%)HR+/HER2-组PIK3CA突变,36 例(51.43%)非HR+/HER2-组突变,二者PIK3CA突变分布有明显差异(P<0.05).PIK3CA突变患者病死率高于PIK3CA野生型(P<0.05).结论 PIK3CA突变与乳腺癌分子分型、Ki67 增值指数及预后相关,可为患者精准治疗提供参考.
Objective To find the correlation between phosphatidylinositol kinase-3 catalytic subunit A gene(PIK3CA)mutation and pathological features as well as clinical prognosis of breast cancer.Methods The patho-logical data of 181 patients diagnosed with invasive breast cancer from January 2018 to January 2020 were collected.The estrogen receptor(ER),progestogen receptor(PR),human epidermal growth factor receptor-2(HER2),Ki67 were examined by immuno-histochemistry(IHC).Mutation of exon 9 and exon 20 of PIK3CA were examined by quantitative real-time PCR(qPCR).Results Among 181 cases of invasive breast cancer,70 cases had PIK3CA mutation with 31 cases(44.28%)showed exon 9 mutations and 39 cases(55.71%)showed exon 20 mutations.The difference between PIK3CA mutation and their distribution in molecular typing of breast cancer was statistically significant(P<0.05).The expression of PIK3CA mutation in breast cancer with different Ki67 expression was sig-nificantly different(P<0.05).There were 34 cases(48.57%)showed PIK3CA mutations in the HR+/HER2 group and 36 cases(51.43%)of non HR+/HER2 group mutations.There was a statistically significant difference in the distribution of PIK3CA mutations between 2 groups(P<0.05).The death rate of PIK3CA mutation cases was higher than that of PIK3CA wild type cases(P<0.05).Conclusions PIK3CA mutation is associated with molecular typ-ing,Ki67 increment index and prognosis of breast cancer.Detection of PIK3CA mutation provides potential support to the development of precise treatment of breast cancer patients.
依合里曼·买买提;曹燕珍;王翠翠;岳娜;梁莉萍
新疆医科大学附属肿瘤医院 病理科,新疆 乌鲁木齐 830011
临床医学
乳腺癌磷脂酰肌醇激酶-3-催化亚基α(PIK3CA)雌激素受体孕激素受体人表皮生长因子受体2
breast cancerphosphatidylinositol kinase-3-catalytic subunit(PIK3CA)estrogen receptorprogestogen receptorhu-man epidermal growth factor receptor 2
《基础医学与临床》 2024 (003)
303-307 / 5
新疆自治区自然科学基金(2020D01C201)
评论